Chewy Inc Earnings - Q1 2027 Analysis & Highlights
Chewy Inc. reported solid Q1 2026 results with continued profitability expansion and market share gains, though the company moderated full-year guidance due to a more challenging consumer environment characterized by pressure on discretionary spending and premiumization, while maintaining confidence in long-term growth prospects driven by strategic initiatives in health services, AI, and fulfillment optimization.
Key Financial Results
Net sales reached $3.36 billion, representing 7.7% year-over-year growth.
Active customers ended the quarter at 21.5 million, up 3.6% year-over-year.
Net sales per active customer (NSPAC) increased to $597, up approximately 4.6% year-over-year on a normalized basis.
Autoship customer sales reached $2.83 billion, increasing over 10% year-over-year and representing 84.4% of total net sales.
Gross margin reached 30.1%, representing approximately 50 basis points of year-over-year expansion.
Adjusted EBITDA reached approximately $253 million, representing a 7.5% adjusted EBITDA margin, up approximately 130 basis points year-over-year.
Adjusted net income was approximately $180 million, translating into adjusted diluted earnings per share of $0.43.
Free cash flow for the quarter was approximately $71 million, increasing over 45% year-over-year.
Nearly 200,000 net customer additions were delivered during the quarter.
Business Segment Results
Chewy Vet Care (CVC) clinics are delivering strong standalone economics while acting as a powerful customer acquisition and retention engine.
Approximately 40% of CVC customers are new to Chewy and these customers tend to reach a year-one NSPAC of approximately $900.
Existing Chewy customers who engage with CVC increase share of wallet meaningfully faster than other cohorts following their first visit.
SmartPak acquisition closed in the first quarter with revenue contribution in line with the previously communicated $80 million net sales expectation for the full year 2026.
Modern Animal acquisition closed shortly after quarter-end, adding a highly complementary and well-established footprint with above industry unit economics.
Capital Allocation
Approximately $200 million of share repurchases were deployed under the existing program during the quarter.
Capital expenditures were approximately $38 million in Q1.
A $600 million term loan B transaction was launched earlier today to enhance financial flexibility.
Cash, cash equivalents and marketable securities ended the quarter at approximately $520 million with over $1 billion of total available liquidity inclusive of the revolving credit facility.
The company intends to maintain a conservative balance sheet and over time, target net leverage below 2x adjusted EBITDA.
Industry Trends and Dynamics
Pet remains a resilient category driven by recurring non-discretionary needs and strong emotional attachment.
Pet healthcare represents approximately $54 billion of TAM, including over $40 billion associated with in-clinic products and veterinary services alone.
Chewy continues to steadily gain share despite a more challenged consumer backdrop.
Industry-level trends in Q1 showed weakening trends within the overall pet food and supplies from an impressions index point of view.
E-commerce continues to take strength in the pet category.
Competitive Landscape
Chewy's value proposition remains exceptionally strong, featuring industry-leading convenience, highly competitive pricing, trusted service, deep assortment and a recurring Autoship ecosystem.
Chewy continues to gain share with an increasingly larger pet TAM by leveraging assets and initiatives across Autoship, Health, Vet Care, AI, fulfillment and customer experience.
The company is not seeing any change to the competitive environment and keeps competitors in the rear-view mirror while focusing on its proposition and customers.
Pricing or promotional intensity remains rational and consistent with what has been seen for quite some time.
Chewy's structural advantages embedded across the platform continue to strengthen the competitive moat.
Macroeconomic Environment
The consumer environment weakened in the latter parts of the quarter.
Consumers are growing more discerning, driven in part by elevated fuel prices and broader macroeconomic pressures.
The consumer pet environment has become incrementally more challenged since the company initially established its fiscal 2026 outlook earlier in the year.
A modest level of incremental pressure on premiumization and product attach rates is being observed amongst the current customer base, resulting in a short-term NSPAC headwind.
The company is seeing more pressure on discretionary attachment and premiumization behavior across portions of the customer base, resulting in slower NSPAC growth than originally anticipated.
Growth Opportunities and Strategies
Chewy Health and Chewy Vet Care represent one of the largest and most compelling long-term opportunities for the company.
The Modern Animal acquisition accelerates the expansion of CVC and unlocks multiple avenues to accelerate clinic growth, combining CVC's organic growth with Modern Animal's existing footprint and development pipeline.
Combined, the company expects to operate approximately 60 clinics exiting fiscal 2026 with embedded revenue contribution approaching approximately $290 million at a steady state.
AI represents a meaningful opportunity for Chewy both from a customer experience perspective and from an operational efficiency standpoint.
AI is being embedded across multiple layers of the business, including customer service, pharmacy operations, fulfillment and marketing workflows.
AI-driven efficiencies are expected to contribute a low tens of millions of dollars in benefit in fiscal 2026, with a more meaningful ramp expected into 2027 and beyond.
Sponsored ads continue to be a driver of margin expansion, with the company exiting last year at roughly the midpoint of its growth curve with an overall expectation of 1% to 3%.
The company's long-term framework for margin expansion remains unchanged, with Chewy continuing to believe it has a unique and differentiated operating model that combines a leading recurring revenue engine with a highly scaled fulfillment and health platform.
The company remains on track to reach its 10% adjusted EBITDA margin target over time.
Financial Guidance and Outlook
For fiscal 2026, the company now expects net sales of between approximately $13.40 billion and $13.55 billion, representing approximately 6.3% to 7.5% year-over-year growth.
The updated guidance includes an expected net sales contribution of approximately $80 million from SmartPak and approximately $70 million from Modern Animal for fiscal year 2026.
The company now expects active customer additions to trend towards the lower end of its previously stated range of approximately 150,000 to 250,000 net adds per quarter.
The company is maintaining its full year fiscal 2026 adjusted EBITDA margin guidance range at 6.6% to 6.8%, or approximately 100 basis points of year-over-year expansion at the midpoint.
At the midpoints of the guidance ranges, this implies approximately $900 million of adjusted EBITDA for the year.
For the second quarter of fiscal 2026, the company expects net sales between approximately $3.30 billion and $3.33 billion, representing approximately 6% to 7% year-over-year growth.
For the second quarter, the company expects adjusted EBITDA margin of between 6.3% and 6.4%, representing approximately 50 basis points of year-over-year expansion at the midpoint.
The company expects adjusted diluted earnings per share for the second quarter to be approximately $0.36.
For the full year 2026, the company continues to expect share-based compensation expense, including related taxes, to remain broadly flat year-over-year.
The company is lowering its weighted average diluted shares outstanding by 5 million shares and now expects to end the year with approximately 420 million shares.
Net interest expense is expected at approximately $10 million to $15 million given the interest expense on the recently launched term loan.
An effective tax rate in the range of approximately 24% to 26% is expected.
Strategic Initiatives and Operational Performance
Adjusted EBITDA flow through exceeded 25%, reflecting continued strength across multiple areas of the business, including sponsored ads, category mix, supply-chain efficiencies, marketing productivity, OpEx discipline and improving operating leverage across the network.
The underlying drivers of profitability expansion remain structural in nature, including the expansion of sponsored ads, product mix shift into higher margin categories, including health and operating expense leverage from automation and scale.
Veterinary teams deliver industry-leading productivity metrics supported by technology-enabled workflows and AI-assisted tools, resulting in vet retention and employee satisfaction that outperforms peers.
Approximately 90 basis points of year-over-year SG&A leverage was delivered, reflecting continued operating discipline, fulfillment productivity improvements driving down variable costs and early benefits from technology and AI-enabled efficiencies.
Advertising and marketing expense was approximately $206 million or 6.1% of net sales, reflecting modest leverage year-over-year.
The company's marketing strategy remains focused on profitable customer acquisition and long-term lifetime value generation, with strong returns across both lower and upper funnel investments.
